Skip navigation.
Cappolino, Dodd, Krebs, LLP

www.AsbestosLaw.com

No Fee Until We Win
1-(888)-MESO-FIRM

1-(888)-637-6347

Serving Clients Nationwide

Rss Feed Twitter Link Facebook Link Linked In Link



Posts Tagged ‘cancer’

Biomarkers May Help Detect Metastasis With Melanoma

Monday, April 25th, 2011

According to the Doctors Lounge, a new study has found that biomarkers may predict metastasis in people with melanoma. A set of plasma biomarkers may be useful in predicting which patients are at risk for metastasis, according to a study published in the Clinical Cancer Research.

Harriet M. Kluger, M.D. of the Yale Cancer Center in Connecticut and a team of researchers measured plasma proteins in 108 metastatic melanoma patients and 108 patients with resected stage I or II disease. The group studied protein levels in the former group.

The researchers found seven biomarkers, all which were higher in metastatic melanoma patients than in those with early-stage of the cancer. 81 percent of the early-stage patients had no marker elevation. In 69 percent of those with metastatic disease at least one marker had an elevation.

The team used blood tests to predict the risk of metastasis with melanoma, which would be a much cheaper method than periodic imaging tests used today. According to the Association for Cancer Research, 68,130 Americans were diagnosed with melanoma in 2010, and 8,700 died of the skin cancer. Most deaths from melanoma result from metastasis.

TV broadcaster Kerry Smith died this week from melanoma. She had worked at The Breeze radio station and presented on Radio Pacific and RadioLive, and formerly worked on MediaWorks. The Breeze FM presenter took medical leave in January, saying she wanted to focus on her treatment and recovery from skin cancer. Melanoma is the most dangerous type of skin cancer and leading cause of death from skin disease.

New Technique May Detect Mesothelioma in Early Stages

Thursday, April 14th, 2011

According to Asbestos News, a study conducted by the New York University Langone Medical Center and sponsored by the National Cancer Institute has found promising results in regards to a technique used to detect mesothelioma in its early stages. Mesothelioma is a deadly cancer, often discovered in late stages and decades after initial exposure to asbestos. The cancer’s late discovery usually leads to poor diagnosis and survival rate.

A new technique created by Somalogic uses SOMAmers, or chemically modified single-stranded DNA molecules that bind only to targeted proteins, which the researchers used to diagnose malignant mesothelioma. The researchers conducted a blind test involving 90 blood samples from patients with malignant mesothelioma and 80 from individuals who have been exposed to asbestos.

According to the study, the SOMAmers detect the presence and quantity of 19 protein biomarkers that manifest themselves in earlier malignant pleural mesothelioma. The results appeared to be promising, according to the study, SOMAmers detected 15 of the 19 stage one or two malignant pleural mesothelioma cases amongst the included blood samples.

The lead researchers of the Langone Medical Center study said that patients with early stage 1 mesothelioma appear to benefit the most from this technique. However, early detection may help in finding a successful treatment to combat the stubborn disease.

Man Wins $90 Million In Mesothelioma Lawsuit

Monday, March 21st, 2011

According to Madison County Record, a former pipe fitter has won an award of $90 million against several companies that allegedly conspired to hide asbestos exposure and its dangers from employees. Charles Gillenwater received an award from an Illinois jury against Honeywell International, Inc, Pneumo Abex, Owens-Illinois Inc. and John Crane Inc. The jury awarded Gillenwater $9.6 in compensatory damages and $80 million in punitive damages, with $40 million to be paid out by Owens-Illinois.

According to the lawsuits, Honeywell, Pneumo Abex and Owens-Illinois conspired to supress information on dangers of asbestos exposure and its side effects. The plaintiff alleged the companies agreed not to warn workers or the public of asbestos hazards.

The Associated Press has reported that Owens-Illinois, the largest maker of glass containers, plans to appeal the verdict. The company denies that it conspired to hide information about asbestos dangers and says that none of its products have shown to have been a factor in Gillenwater’s mesothelioma cancer.

Gillenwater claimed he contracted mesothelioma after he was exposed to asbestos while working as a pip fitter in several locations. He had not been a direct employee of Owens-Illinois or worked in its facilities. Gillenwater, 59, felt that the companies intentionally hid the facts about asbestos and the dangers of the hazardous mineral fiber. The trial lasted five weeks.

Mesothelioma is an aggressive and often terminal cancer that is contracted through inhaling asbestos fibers. It is most commonly contracted on the job, and takes several decades to show first symptoms, at which time is it very likely too late to successfully respond to any type of treatment.

Mesothelioma Affected by MT1-MMP Enzyme

Monday, December 6th, 2010

A malignant mesothelioma diagnosis is usually considered a death sentence. However there are clinical trials, and studies going on every day to help treat this aggressive cancer. Between 2,000 and 3,000 people are diagnosed with Mesothelioma each year in the United States alone. As with other asbestos relates diseases mesothelioma has a long latency period with symptoms not appearing until as much as 20 years after exposure.
This long latency period often means that before a diagnosis is made based on the symptoms that appear the cancer is in an advanced stage. The symptoms of mesothelioma are similar to many other lung conditions which make it hard to diagnose. No cure had been found, but studies have found that it is possible to improve the life expectancy of patients who are diagnosed early.
A study has been performed that shows a relationship between the enzyme MT1-MMP and the local growth pattern of mesothelioma. This discovery reveals that the presence of this enzyme promotes angiogenesis which allows the cancer cells to spread. This leaves researchers with a whole new venue to develop a treatment method that will eliminate the presence of this enzyme and possibly shut down the spread of the mesothelioma cells.
Once developed this could prove to be an effective treatment option to promote longevity and slow the spread of the cancer. With all the different trials, studies and treatments being explored the mesothelioma diagnosis is becoming slowly less final and definitive. Each small piece of knowledge and each tiny advance helps in the fight against this deadly disease.